Table 1 CD73 and CD39: Predictive and Prognostic Biomarkers
| Â | Tumor Type | Findings | # of Patients | Study Author |
|---|---|---|---|---|
CD73 | ||||
Negatively prognostic | NSCLC (stage I-III) | High CD73 expression was an independent risk factor for decreased overall survival and dereased recurrence-free survival | 642 | Inoue, et al. [54] |
Prostate Cancer | CD73 expression in normal tissue was a negative prognostic factor for prostate-infiltrating CD8(+) cells. However, high expression of CD73 in tumor stroma was associated with longer recurrence-free survival | 285 | Leclerc, et al. [55] | |
Breast Cancer (Triple Negative) | CD73 expression is associated with anthracycline resistance and poor prognosis | 6000 | Loi, et al. [56] | |
High-Grade Serous Ovarian Cancer | High levels of CD73 are associated with shorter disease-free survival and overall survival | 1581 | Gaudreau, et al. [57] | |
Colorectal Cancer (stage I-IV) | High expression of CD73 predicts poor survival | 223 | Wu, et al. [58] | |
Gastric Cancer (stage I-IV) | High expression CD73 is associated with lowered overall survival | 68 | Lu, et al. [65] | |
Melanoma (Stage IV) | High soluble CD73 activity was associated with poor overall survival and poor progression-free survival | 37 | Morello, et al. [59] | |
Head and Neck Cancer (stage I-IV) | High levels of CD73 are associated with reduced overall survival | 162 | Ren, et al. [60] | |
Renal Cell Cancer (Stage I-IV) | High expression of CD73 is associated with disease progression and shortened overall survival | 189 | Yu, et al. [2] | |
Positively prognostic | Nonmuscle-Invasive Urothelial Bladder Cancer | High CD73 iactivity was associated with favorable clinicopathological features. Furthermore, predicts better outcome in the subgroup of pTa and pT1 tumors. | 174 | Wettstein, et al. [61] |
Breast Cancer (stage I-III) | CD73 expression strongly correlated with longer disease-free survival and overall survival | 136 | Supernat, et al. [62] | |
Endometrial Carcinoma (endometrial endometrioid carcinomas, Grade 1–3) and nonendometrioid uterine papillary serous carcinomas | CD73 is markedly downregulated in poorly differentiated and advanced-stage disease compared with levels in normal endometrium and low-grade tumors | 49 | Bowser, et al. [64] | |
Colorectal cancer (Stage IV) | High CD73 expression was associated with longer progression free survival from cetuximab treatment in patients with KRAS-WT and KRAS-mutant tumors | 238 | Cushman, et al. [63] | |
CD39 | ||||
Negatively prognostic | Gastric Cancer (stage I-IV) | High CD39 expression is a predictor of poor outcome following radical resection | 101 | Cai, et al. [69] |
Hepatocellular carcinoma | High CD39 expression is an independent indicator of decreased overall suvival after radical resection | 324 | Cai, et al. [70] | |
Chronic lymphocytic leukemia | CD39 expression on CD4+ lymphocytes are increased in the peripheral blood of patients with CLL and correlates with advanced stage of disease | 62 | Perry, et al. [71] | |